MA49700A - Procédé amélioré pour la préparation de dérivés d'aminopyrimidine - Google Patents

Procédé amélioré pour la préparation de dérivés d'aminopyrimidine

Info

Publication number
MA49700A
MA49700A MA049700A MA49700A MA49700A MA 49700 A MA49700 A MA 49700A MA 049700 A MA049700 A MA 049700A MA 49700 A MA49700 A MA 49700A MA 49700 A MA49700 A MA 49700A
Authority
MA
Morocco
Prior art keywords
preparation
improved process
aminopyrimidine derivatives
aminopyrimidine
derivatives
Prior art date
Application number
MA049700A
Other languages
English (en)
Other versions
MA49700B1 (fr
Inventor
Yoon-Ah Hwang
Hyun Ju
Ja-Heouk Khoo
Seong-Ran Lee
Jong-Chul Lim
Sang-Ho Oh
Dae-Gyu Park
su-min Park
Woo-Seob Shin
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65040211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49700(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of MA49700A publication Critical patent/MA49700A/fr
Publication of MA49700B1 publication Critical patent/MA49700B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2284—Compounds with one or more Sn-N linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
MA49700A 2017-07-28 2018-07-25 Procédé pour la préparation de n-(5-((4-(4-((diméthylamino)méthyl)-3-phényl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-méthoxy-2-morpholinophényl)acrylamide par réaction de l'amine correspondante avec un 3-halo-propionyl chloride MA49700B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170096212 2017-07-28
PCT/KR2018/008379 WO2019022485A1 (fr) 2017-07-28 2018-07-25 Procédé amélioré pour la préparation de dérivés d'aminopyrimidine

Publications (2)

Publication Number Publication Date
MA49700A true MA49700A (fr) 2021-03-17
MA49700B1 MA49700B1 (fr) 2023-09-27

Family

ID=65040211

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49700A MA49700B1 (fr) 2017-07-28 2018-07-25 Procédé pour la préparation de n-(5-((4-(4-((diméthylamino)méthyl)-3-phényl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-méthoxy-2-morpholinophényl)acrylamide par réaction de l'amine correspondante avec un 3-halo-propionyl chloride

Country Status (32)

Country Link
US (4) US10889578B2 (fr)
EP (1) EP3658552B1 (fr)
JP (2) JP7228562B2 (fr)
KR (1) KR102688084B1 (fr)
CN (2) CN111315742B (fr)
AU (2) AU2018308038B2 (fr)
BR (1) BR112020001278A2 (fr)
CA (1) CA3070069C (fr)
CO (1) CO2020000374A2 (fr)
DK (1) DK3658552T3 (fr)
EA (1) EA202090383A1 (fr)
ES (1) ES2962961T3 (fr)
FI (1) FI3658552T3 (fr)
HR (1) HRP20231191T1 (fr)
HU (1) HUE063533T2 (fr)
IL (2) IL271973B (fr)
LT (1) LT3658552T (fr)
MA (1) MA49700B1 (fr)
MD (1) MD3658552T2 (fr)
MX (2) MX393995B (fr)
MY (1) MY198379A (fr)
PH (1) PH12020500059A1 (fr)
PL (1) PL3658552T3 (fr)
PT (1) PT3658552T (fr)
RS (1) RS64654B1 (fr)
SA (2) SA520411112B1 (fr)
SG (1) SG11201913517UA (fr)
SI (1) SI3658552T1 (fr)
SM (1) SMT202300339T1 (fr)
UA (1) UA125317C2 (fr)
WO (1) WO2019022485A1 (fr)
ZA (1) ZA202001250B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201913517UA (en) 2017-07-28 2020-02-27 Yuhan Corp Improved process for preparing aminopyrimidine derivatives
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
US11879013B2 (en) 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
JP7783182B2 (ja) 2020-02-12 2025-12-09 ヤンセン バイオテツク，インコーポレーテツド ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療
US12138351B2 (en) 2020-04-14 2024-11-12 Janssen Biotech, Inc. Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
US11780824B2 (en) * 2020-12-16 2023-10-10 Scinopharm Taiwan, Ltd. Process for preparing osimertinib or a salt thereof
CN116199701A (zh) * 2023-02-27 2023-06-02 安徽中医药大学 一种基于分子内自由基环加成制备吡唑并恶嗪草酮类化合物及其制备方法
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
AU2024337472A1 (en) 2023-09-05 2026-04-16 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer
WO2026042017A1 (fr) 2024-08-19 2026-02-26 Janssen Biotech, Inc. Amivantamab en association avec le lazertinib pour le traitement du cancer du poumon non à petites cellules (cpnpc)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
AR037438A1 (es) 2001-11-27 2004-11-10 Wyeth Corp 3-cianoquinolinas como inhibidores de egf-r y her2 quinasas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AU2005309019A1 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
US20060270600A1 (en) 2005-05-26 2006-11-30 Eisuke Mekada Anti-cancer agents
TW200736232A (en) 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
ES2555803T3 (es) 2006-10-23 2016-01-08 Cephalon, Inc. Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
WO2008124085A2 (fr) 2007-04-03 2008-10-16 Exelixis, Inc. Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2
NZ603525A (en) * 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
EP2488503A1 (fr) 2009-10-12 2012-08-22 Myrexis, Inc. Composés d'amino-pyrimidine en tant qu'inhibiteurs de tbkl et ou d'ikk epsilon
EA024729B1 (ru) * 2009-11-13 2016-10-31 Джиноско Киназные ингибиторы
JP5802676B2 (ja) 2009-12-04 2015-10-28 センワ バイオサイエンシズ インコーポレイテッド Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
MY170236A (en) 2010-10-06 2019-07-11 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
WO2012061303A1 (fr) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Composés hétéroaryle et leurs utilisations
UA112425C2 (uk) 2010-12-13 2016-09-12 Еррей Біофарма Інк. ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ
EP4119551A1 (fr) 2011-07-27 2023-01-18 Astrazeneca AB Composés de 2-(anilino 2,4,5-substitué)pyrimidine
TW201332989A (zh) 2011-12-23 2013-08-16 Millennium Pharm Inc 雜芳基化合物及其用途
BR112014015720B1 (pt) 2011-12-30 2020-03-17 Hanmi Pharm. Co., Ltd. Derivados de tieno[3,2-d]pirimidina, composição farmacêutica e uso dos mesmos para a prevenção ou tratamento de uma doença causada por ativação anormal de uma proteína quinase
CN104860891B (zh) 2014-02-25 2017-06-30 上海海雁医药科技有限公司 芳氨基嘧啶类化合物及其应用以及由其制备的药物组合物和药用组合物
JP6468611B2 (ja) 2014-05-13 2019-02-13 アリアド ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
WO2015188777A1 (fr) 2014-06-12 2015-12-17 Shanghai Fochon Pharmaceutical Co Ltd Inhibiteurs particuliers de protéines kinases
HUE054848T2 (hu) 2014-10-13 2021-09-28 Yuhan Corp Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
AR102263A1 (es) 2015-10-14 2017-02-15 Yuhan Corp Compuestos y composiciones para la modulación de las actividades quinasa del receptor de egf mutante
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
DE102017212159A1 (de) 2017-07-14 2019-01-17 Krones Aktiengesellschaft Verfahren und Vorrichtung zur Handhabung von Stückgütern, Artikeln und/oder Gebinden
WO2019022486A1 (fr) 2017-07-28 2019-01-31 Yuhan Corporation Nouveaux intermédiaires utiles pour la synthèse de dérivés d'aminopyrimidine, leur procédé de préparation et procédé de préparation de dérivés d'aminopyrimidine à l'aide de ceux-ci
MY201038A (en) * 2017-07-28 2024-01-31 Yuhan Corp Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
SG11201913517UA (en) 2017-07-28 2020-02-27 Yuhan Corp Improved process for preparing aminopyrimidine derivatives
CN108826170A (zh) 2018-06-26 2018-11-16 深圳市远润欣电子有限公司 局部全般照明的模式、控制方法及台灯

Also Published As

Publication number Publication date
IL292429B1 (en) 2023-05-01
JP2023027091A (ja) 2023-03-01
CN116987112B (zh) 2025-12-19
EP3658552B1 (fr) 2023-09-13
US12187714B2 (en) 2025-01-07
MX393995B (es) 2025-03-24
US20210269427A1 (en) 2021-09-02
PT3658552T (pt) 2023-11-03
ZA202001250B (en) 2023-04-26
SI3658552T1 (sl) 2023-11-30
UA125317C2 (uk) 2022-02-16
IL271973B (en) 2022-08-01
JP7539451B2 (ja) 2024-08-23
MA49700B1 (fr) 2023-09-27
LT3658552T (lt) 2023-11-27
KR20190013553A (ko) 2019-02-11
AU2018308038B2 (en) 2022-02-03
US11708362B2 (en) 2023-07-25
US20200165236A1 (en) 2020-05-28
SA522431428B1 (ar) 2024-10-21
KR102688084B1 (ko) 2024-07-24
MD3658552T2 (ro) 2024-02-29
US10889578B2 (en) 2021-01-12
BR112020001278A2 (pt) 2020-07-21
SA520411112B1 (ar) 2022-02-21
HRP20231191T1 (hr) 2024-02-02
RS64654B1 (sr) 2023-10-31
US11286253B2 (en) 2022-03-29
ES2962961T3 (es) 2024-03-22
CN111315742A (zh) 2020-06-19
EA202090383A1 (ru) 2020-06-15
SMT202300339T1 (it) 2023-11-13
AU2022202936B2 (en) 2023-04-27
IL271973A (en) 2020-02-27
EP3658552A1 (fr) 2020-06-03
CN116987112A (zh) 2023-11-03
JP2020528440A (ja) 2020-09-24
US20220281861A1 (en) 2022-09-08
PL3658552T3 (pl) 2024-02-19
IL292429B2 (en) 2023-09-01
MY198379A (en) 2023-08-28
EP3658552A4 (fr) 2021-06-23
NZ761156A (en) 2024-01-26
CA3070069C (fr) 2024-02-20
JP7228562B2 (ja) 2023-02-24
SG11201913517UA (en) 2020-02-27
AU2018308038A1 (en) 2020-01-30
IL292429A (en) 2022-06-01
MX2022008743A (es) 2023-02-02
CA3070069A1 (fr) 2019-01-31
HUE063533T2 (hu) 2024-01-28
PH12020500059A1 (en) 2020-09-28
AU2022202936A1 (en) 2022-05-26
CO2020000374A2 (es) 2020-05-05
FI3658552T3 (fi) 2023-11-16
DK3658552T3 (da) 2023-11-20
CN111315742B (zh) 2023-09-01
WO2019022485A1 (fr) 2019-01-31
US20230312545A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
EP3658552A4 (fr) Procédé amélioré pour la préparation de dérivés d'aminopyrimidine
EP3677589A4 (fr) Procédé amélioré de production d'un conjugué anticorps-médicament
EP3647310A4 (fr) Procédé de préparation de 2,5-furandiméthylcarboxylate à partir d'hydroxyméthylfurfural
EP3315512A4 (fr) Procédé pour la préparation sélective d'un conjugué anticorps-médicament
MA51988A (fr) Procédé pour la préparation de composés utiles à traiter l'amyotrophie spinale
EP3683205A4 (fr) Procédé de préparation d'isocyanate aliphatique
EP3706725A4 (fr) Processus pour la préparation de tapinarof
EP3658553A4 (fr) Nouveaux intermédiaires utiles pour la synthèse de dérivés d'aminopyrimidine, leur procédé de préparation et procédé de préparation de dérivés d'aminopyrimidine à l'aide de ceux-ci
EP3606533A4 (fr) Procédé de préparation de dérivés sulfonylcarbamate d'acides biliaires
MA45768A (fr) Procédé pour la préparation de compositions d'immunoglobulines
EP3766869A4 (fr) Procédé simple de préparation d'avibactam
EP3808732A4 (fr) Procédé de préparation d'isocyanates aliphatiques
EP3431520A4 (fr) Procédé de préparation d'un copolymère d'oxyméthylène
EP3696168A4 (fr) Procédé de préparation de 2-chloro-5-trifluorométhylpyridine
MA51870A (fr) Procédé pour la préparation de composés coupleurs de médicaments
EP3511313A4 (fr) Procédé de préparation de 1,3-cyclohexanediméthanol
EP4021920A4 (fr) Procédé amélioré pour la préparation de chlorhydrate d'ételcalcétide
EP3902792A4 (fr) Procédé de préparation d'anthranilamides
MA51510A (fr) Procédés de préparation de dérivés d'indolinobenzodiazépine
EP3663322A4 (fr) Procédé de préparation d'oligomère de butène
EP3354701A4 (fr) Procédé de préparation d'une composition de revêtement par électrodéposition cationique
EP3314001A4 (fr) Procédés et compositions pour la préparation d'éphédrine et de composés alcaloïdes apparentés
EP3533856A4 (fr) Procédé de préparation d'hexadécahydropyrène
MA51339A (fr) Procédé de préparation de composés pyrimidinyl-4-aminopyrazole
EP3666756A4 (fr) Procédé de préparation de lévétiracétam